MUC16 and ovarian carcinoma: CA-125 is an FDA-approved serum biomarker used in monitoring cancer progression and treatment response, particularly in ovarian cancer (Bottoni and Scatena, 2015; Li et al., 2018; Charkhchi et al., 2020).